Clinical Research Directory

Inclusion Criteria: 1. Adults (male and female) aged between 18 and 65 years. 2. Experiencing signs and symptoms suggestive of stress (e.g., difficulty, concentrating, physical exhaustion, anxiety, restlessness, insomnia, headache, fatigue, loss of appetite, worry, sweating, mental confusion, etc.). 3. Hamilton Anxiety Rating Scale (HAM-A) total score between 14 and 30 at the screening/randomization visit. 4. Perceived Stress Scale (PSS) score ≥13 at the screening/randomization visit. 5. BMI between 20 and 35. 6. No plan to commence new treatments over the study period. 7. Medication-free (any medications are known to affect stress and anxiety) for at least 4 weeks. Use of analgesics (once a week) or contraceptive pills are permissible. 8. Must have the ability and willingness to sign an informed consent and to comply with all study procedures. Exclusion Criteria: 1. Patients receiving any of the medications known to affect stress and anxiety (corticosteroids, antidepressants, antipsychotics, mood stabilizers, and anti-epileptic medications) during 4 weeks prior to screening. 2. Patients having a total score of less than 14 on HAM-A at screening. 3. Patients currently (or within the past 4 weeks prior to screening) taking any over-the-counter use of herbal extracts such as Ginkgo Biloba, St. John's Wort, Omega-3, etc. 4. Patients with a depressive episode, suicidal tendency, panic disorder, social phobia, obsessive-compulsory disorder; alcohol dependency; schizophrenia, and mania. 5. Patients with known post-traumatic stress disorder (PTSD) and Generalized Anxiety Disorder (GAD). 6. Patients who have an established practice of meditation and relaxation techniques for three or more months. 7. Patients with known clinically significant acute unstable hepatic, renal, cardiovascular, or respiratory disease that will prevent participation in the study. 8. Patients with a history of alcohol, tobacco dependence, or any substance abuse. 9. Pregnant and lactating women or suspected to be pregnant. 10. Patients with known hypersensitivity to Ashwagandha. 11. Patients who had participated in other clinical trials during the previous 3 months. 12. Patients who have any clinical condition, according to the investigator who does not allow safe fulfilment of clinical trial protocol.